Suven Life Sciences Limited (SUVEN) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.368x

Based on the latest financial reports, Suven Life Sciences Limited (SUVEN) has a cash flow conversion efficiency ratio of -0.368x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-1.03 Billion ≈ $-11.18 Million USD) by net assets (Rs2.81 Billion ≈ $30.42 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Suven Life Sciences Limited - Cash Flow Conversion Efficiency Trend (2005–2025)

This chart illustrates how Suven Life Sciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SUVEN liabilities breakdown for a breakdown of total debt and financial obligations.

Suven Life Sciences Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Suven Life Sciences Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Nanjing Zhongbei Group Co Ltd
SHE:000421
0.036x
Zhongbai Holdings Group Co Ltd
SHE:000759
-0.009x
Guangdong Tecsun Science & Technology Co Ltd
SHE:002908
0.012x
CapitaLand Malaysia Mall Trust
KLSE:5180
0.021x
KT Submarine Co. Ltd
KQ:060370
0.022x
Shanghai Shen Lian Biomedical Corp
SHG:688098
0.015x
Diversified Royalty Corp
TO:DIV
0.046x
Hualan Group Co Ltd
SHE:301027
0.118x

Annual Cash Flow Conversion Efficiency for Suven Life Sciences Limited (2005–2025)

The table below shows the annual cash flow conversion efficiency of Suven Life Sciences Limited from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see SUVEN market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-03-31 Rs1.10 Billion
≈ $11.89 Million
Rs-1.48 Billion
≈ $-16.06 Million
-1.350x -215.69%
2024-03-31 Rs2.70 Billion
≈ $29.20 Million
Rs-1.15 Billion
≈ $-12.49 Million
-0.428x -55.59%
2023-03-31 Rs3.75 Billion
≈ $40.59 Million
Rs-1.03 Billion
≈ $-11.16 Million
-0.275x +79.28%
2022-03-31 Rs961.45 Million
≈ $10.40 Million
Rs-1.28 Billion
≈ $-13.79 Million
-1.327x -49.20%
2021-03-31 Rs1.08 Billion
≈ $11.68 Million
Rs-960.24 Million
≈ $-10.38 Million
-0.889x +34.25%
2020-03-31 Rs1.43 Billion
≈ $15.50 Million
Rs-1.94 Billion
≈ $-20.96 Million
-1.352x -3261.03%
2019-03-31 Rs8.31 Billion
≈ $89.87 Million
Rs355.49 Million
≈ $3.84 Million
0.043x -53.06%
2018-03-31 Rs7.67 Billion
≈ $82.99 Million
Rs699.36 Million
≈ $7.56 Million
0.091x -44.15%
2017-03-31 Rs6.67 Billion
≈ $72.13 Million
Rs1.09 Billion
≈ $11.77 Million
0.163x +39.04%
2016-03-31 Rs5.95 Billion
≈ $64.40 Million
Rs698.78 Million
≈ $7.56 Million
0.117x -54.10%
2015-03-31 Rs5.59 Billion
≈ $60.49 Million
Rs1.43 Billion
≈ $15.46 Million
0.256x -44.27%
2014-03-31 Rs2.64 Billion
≈ $28.60 Million
Rs1.21 Billion
≈ $13.12 Million
0.459x +130.90%
2013-03-31 Rs1.54 Billion
≈ $16.70 Million
Rs306.86 Million
≈ $3.32 Million
0.199x -24.39%
2012-03-31 Rs1.28 Billion
≈ $13.79 Million
Rs335.07 Million
≈ $3.62 Million
0.263x +503.70%
2011-03-31 Rs1.27 Billion
≈ $13.71 Million
Rs55.16 Million
≈ $596.55K
0.044x -60.24%
2010-03-31 Rs1.18 Billion
≈ $12.77 Million
Rs129.25 Million
≈ $1.40 Million
0.109x -63.45%
2009-03-31 Rs1.14 Billion
≈ $12.38 Million
Rs342.73 Million
≈ $3.71 Million
0.299x +709.03%
2008-03-31 Rs1.06 Billion
≈ $11.51 Million
Rs39.38 Million
≈ $425.92K
0.037x -76.86%
2007-03-31 Rs1.02 Billion
≈ $10.98 Million
Rs162.41 Million
≈ $1.76 Million
0.160x +161.76%
2006-03-31 Rs902.12 Million
≈ $9.76 Million
Rs55.13 Million
≈ $596.25K
0.061x +135.07%
2005-03-31 Rs811.85 Million
≈ $8.78 Million
Rs21.11 Million
≈ $228.26K
0.026x --

About Suven Life Sciences Limited

NSE:SUVEN India Drug Manufacturers - Specialty & Generic
Market Cap
$531.49 Million
Rs49.15 Billion INR
Market Cap Rank
#12220 Global
#574 in India
Share Price
Rs211.88
Change (1 day)
-2.51%
52-Week Range
Rs126.65 - Rs296.60
All Time High
Rs296.60
About

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candida… Read more